Basel, Switzerland – 20.08.2018 – ABBA Therapeutics successfully closed “Seed B” financing round with European investors. The raised fund will be used to accelerate the preclinical efficacy study with cutting-edge animal models and advance two lead candidates for clinical efficacy study.
About ABBA Therapeutics
ABBA Therapeutics is a Swiss biotechnology company founded in Basel in 2016. ABBA Therapeutics focuses on developing next-generation antibody drugs for cancer immunotherapy. The lead project is to develop therapeutic antibodies targeting a novel immune checkpoint family member across both lymphoid and myeloid lineages for a better and broader response of cancer patients to IO therapies.
Further contact: info@abba-therapeutics.com; www.abba-therapeutics.com
ABBA Therapeutics was selected for BaseLaunch program
Basel, Switzerland – 18.09.2017 – ABBA Therapeutics was selected to participate BaseLaunch program from more than 100 international applications. ABBA Therapeutics will receive non-dilutive funding CHF 10,000 for continuing its pipeline development.
About ABBA Therapeutics
ABBA Therapeutics is a Swiss biotechnology company founded in Basel in 2016. ABBA Therapeutics focuses on developing next-generation antibody drugs for cancer immunotherapy. The lead project is to develop therapeutic antibodies targeting a novel immune checkpoint family member across both lymphoid and myeloid lineages for a better and broader response of cancer patients to IO therapies.
Further contact: info@abba-therapeutics.com; www.abba-therapeutics.com
About BaseLaunch
BaseLaunch was set up in 2017 by BaselArea.swiss and collaborates closely with digital switzerland’s Kickstart Accelerator as its healthcare vertical. BaseLaunch has set itself the task of accelerating the development of promising and pioneering healthcare startups and strengthening the leadership position of the Basel region as the pre-eminent life sciences hub. The accelerator program offers funding, expertise, and infrastructure and industry access to promising new ventures, and integrates them into one of the most dynamic biotech and pharma ecosystems in Europe. BaseLaunch enjoys the backing of healthcare partners Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche as well as other public and private partners. Projects are reviewed by a selection committee from international healthcare industries and investment companies. Further contact: www.baselaunch.ch
About BaselArea.swiss
BaselArea.swiss is the office for promoting innovation and inward investment for the northwest cantons of Basel-Stadt, Basel-Landschaft and Jura. BaselArea.swiss currently has an annual budget of 3.6 million francs, provided by the three cantons and by the State Secretariat for Economic Affairs (SECO). The core function of BaselArea.swiss is to promote the strengths of northwest Switzerland as a center for business and to help both Swiss and foreign entrepreneurs and companies implement their innovation and business projects in the region. With its extensive information platform and regular innovation reports, BaselArea.swiss contributes to the sustainable positioning of the Basel region as a leading center for innovation and commerce. Further contact: Thomas Brenzikofer, thomas.brenzikofer@baselarea.swiss, +41 79 509 84 50
ABBA Therapeutics enters into OmniAb® Platform License Agreement With Ligand
Basel, Switzerland – 28.03.2016 – ABBA Therapeutics AG announces it has entered into a worldwide license agreement with Ligand Pharmaceuticals (NASDAQ: LGND). Under this agreement, ABBA Therapeutics will use OmniAb® platform, an industry-leading technology including OmniRat®, OmniMouse® and OmniFlic®, to generate fully human mono- and bispecific antibodies for developing innovative immuno-oncology therapies. Ligand is to receive an initial access payment, and will be eligible to receive clinical milestone payments and royalties for each successful OmniAb antibody.
About ABBA Therapeutics
ABBA Therapeutics is a Swiss biotechnology company founded in Basel in 2016. ABBA Therapeutics focuses on developing next-generation antibody drugs for cancer immunotherapy. The lead project is to develop therapeutic antibodies targeting a novel immune checkpoint family member across both lymphoid and myeloid lineages for a better and broader response of cancer patients to IO therapies.
Further contact: info@abba-therapeutics.com; www.abba-therapeutics.com
About Ligand Pharmaceuticals (NASDAQ: LGND)
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.
Further contact: investors@ligand.com; www.ligand.com
About OmniAb®
OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. OmniAb includes three transgenic animal platforms for producing mono- and bispecific human therapeutic antibodies. OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as effectively as wildtype animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic® is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The three platforms use patented technology, have broad freedom to operate and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability.
